This article was downloaded by: [Dalhousie University] On: 20 September 2012, At: 01:41 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lsyc20

Synthesis of 6,7-Diacylcoumarins via the Transformation of a Hydroxy into a Carbonyl Group

Antigoni Kotali^a, Ioannis S. Lafazanis^a & Philip A. Harris^b

^a Laboratory of Organic Chemistry, Department of Chemical Engineering, University of Thessaloniki, Thessaloniki, Greece

^b GlaxoSmithKline, Collegeville, Pennsylvania, USA

Version of record first published: 20 Oct 2008.

To cite this article: Antigoni Kotali, Ioannis S. Lafazanis & Philip A. Harris (2008): Synthesis of 6,7-Diacylcoumarins via the Transformation of a Hydroxy into a Carbonyl Group, Synthetic Communications: An International Journal for Rapid Communication of Synthetic Organic Chemistry, 38:22, 3996-4006

To link to this article: http://dx.doi.org/10.1080/00397910802250911

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <u>http://www.tandfonline.com/page/terms-and-conditions</u>

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae, and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand, or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Synthetic Communications[®], 38: 3996–4006, 2008 Copyright © Taylor & Francis Group, LLC ISSN: 0039-7911 print/1532-2432 online DOI: 10.1080/00397910802250911



Synthesis of 6,7-Diacylcoumarins via the Transformation of a Hydroxy into a Carbonyl Group

Antigoni Kotali,¹ Ioannis S. Lafazanis,¹ and Philip A. Harris²

¹Laboratory of Organic Chemistry, Department of Chemical Engineering, University of Thessaloniki, Thessaloniki, Greece ²GlaxoSmithKline, Collegeville, Pennsylvania, USA

Abstract: The synthesis of 6,7-diacylcoumarins is reported via the oxidation of 6-acetyl-7-hydroxycoumarin *N*-acylhydrazones with lead tetraacetate. The procedure involves transformation of hydroxy into an acyl group and formation of a new C–C bond.

Keywords: *N*-acylhydrazones, 6,7-diacyl-2*H*-chromen-2-ones, coumarins, lead tetraacetate, oxidation, transformation

Linear 6,7-disubstituted coumarins, a class of fused-ring heterocycles, also well known as chromen-2-ones, are widely found in the nature and show interesting biological activity.^[1] Generally, naturally occurring coumarins are found in several plants, including grasses, orchids, citrus fruits, and legumes, and are involved in the actions of plant growth hormones and growth regulators, the control of respiration, photosynthesis, and defense against infection.^[2] In addition, these compounds exhibit a variety of pharmacological properties. Among these properties, their cytotoxic effects have been most extensively investigated.^[3] However, they also play an important role in medicine as anti-HIV,^[4] cytotoxic,^[5] anticoagulant,^[6] antibacterial,^[7] oestrogenic,^[8]

Received March 18, 2008.

Address correspondence to Antigoni Kotali, Laboratory of Organic Chemistry, Department of Chemical Engineering, University of Thessaloniki, Thessaloniki 54124, Greece. E-mail: kotali@eng.auth.gr

anti-inflammatory.^[9] antioxidant.^[10] and fluorescent^[11] agents. Furthermore, several coumarins bearing different groups on the aromatic ring were synthesized and tested to find more active analogs. Psoralen and esculetin are typical examples among the natural 6,7-substituted coumarin derivatives with cytotoxic activity.^[3] In addition, the linear furanocoumarins isopimpinellin and imperatorin are ingested regularly as part of the humandiet as they are present in the rind and pulp oflimes, in lemon and lime oils, and in celery, parsnip, and parsley; are analgesic;^[12] and have been found to alter enzyme activities and reduce DNA adduct formation by polycyclic aromatic hydrocarbons in various tissues of mice.^[13,14] On the other hand, 6,7-dimethylcoumarin derivatives are typical examples among the interesting synthetic analogs with antiangiogenic and simultaneous fluorescent activity, giving the ability for both imaging and inhibition against angiogenesis at the same time.^[15] Because the pharmacological and biochemical properties and therapeutic applications of coumarins depend^[2] upon the pattern of substitution and alterations in the structure of coumarins could change their cytotoxic properties, it is not difficult to understand why the design and the synthesis of substituted coumarin derivatives is of great importance to many researchers.

Recently, we synthesized^[16] 7,8-diacylcoumarins in our laboratory, and we would like further to synthesize linear 6,7-diacyl derivatives.

Depending on this knowledge, on our interest in coumarin derivatives,^[16] and on the applications of the reactions of *o*-hydroxy arylketone *N*-acylhydrazones^[17] with lead tetraacetate (LTA) in organic synthesis, we studied the synthesis of 6,7-diacylcoumarins **4** according to Scheme 1. The synthetic scheme proceeds via reaction of 6-acetyl-7-hydroxycoumarin *N*-acylhydrazones **3** with LTA and involves transformation of a hydroxy into a carbonyl group.



Scheme 1. Preparation of 6,7-diacylcoumarins 4.



Scheme 2. Preparation of 6- and 8-acetyl-7-hydroxycoumarin 1 and 6.

Starting coumarin **1** has been reported in the literature as obtained as a mixture with the isomer 7-hydroxy-8-acetylcoumarin **6** under treatment of 7-acetoxycoumarin **5** with aluminum chloride (Scheme 2).^[18]

Recrystallization of this mixture results in the isolation of 7-hydroxy-8-acetylcoumarin 6 in 74% yield as a solid, whereas the desired 6-acetyl derivative 1 remains in the filtrate along with some quantity of 8-acetyl isomer 6 and 7-hydroxycoumarin. Removal of the solvent and subjection of the filtrate mixture to column chromatography afforded the desired 6-acetyl derivative 1 in only minor traces to 5% pure yield, whereas the most quantity of the product is obtained as a mixture with the isomer 7-hydroxy-8-acetylcoumarin. Trying to optimize the yield for coumarin 1, we applied two subsequent purifications via column chromatography as well as recrystallization from ethanol. In this way, 6-acetyl isomer 1 could be isolated in 14% yield. However, because the yield was still low, we decided to run two series of experiments to synthesize 6,7-diacylcoumarins using as the starting carbonyl substrate: (i) pure 6-acetyl-7hydroxycoumarin (method A, Scheme 1) and (ii) the mixture of 6- and 8-acetyl-7-hydroxycoumarin as it was in the filtrate without any further purifications (method B, Scheme 3).

In method A, a series of 6-acetyl-7-hydroxycoumarin N-carbonylhydrazones **3** were prepared in very good yields, 92 to 75% (Scheme 1). Hydrazones **3** are new compounds, and they were identified by their



Scheme 3. Alternative preparation of 6,7-diacylcoumarins 4.

spectral data and by either exact mass measurement or elemental analysis. Hydrazones **3** were subsequently oxidized with LTA to lead to the formation of the desired products **4** in good yields, 60–73%. The reaction conditions, the yields of formation of the new compounds **3** and **4**, and their melting points are presented in Table 1. The desired linear 6,7diacylcoumarins were isolated by column chromatography and identified by their spectral data and by either exact mass measurement or elemental analysis.

In method B, the mixture of 6- and 8-acetyl-7-hydroxycoumarin 1 and 6 was treated with the appropriate hydrazides 2 to produce mixtures of the corresponding hydrazones 3 and 7, which subsequently afforded mixtures of the corresponding 6,7- and 7,8-diacylcoumarins 4 and 8 under treatment with LTA. The desired linear pure 6,7-diacyl-coumarins 4 were isolated by column chromatography in 35–48% yield (Table 1) and identified by comparison of their spectral data with those of the authentic samples prepared by method A. Isomers 8 that were also formed during the reactions are known compounds, and their synthesis was recently reported.^[16]

In addition, reaction of hydrazone **4e** with phenyliodosodiacetate (PID) led to the formation of **4e** in yields comparable to the LTA yield (Table 1). This is in accordance with our previous findings about the transformation of the hydroxy into a carbonyl group.^[17]

Concerning the mechanism of the transformation reactions, it is not unreasonable to assume that it works analogously to the mechanism that we proposed for the transformation of *o*-hydroxyacetophenone *N*-benzoylhydrazone into 1-acetyl-2-benzoylbenzene.^[19]

In conclusion, the transformation of a hydroxy into an acyl group $(1 \rightarrow 3 \rightarrow 4$ in Scheme 1) was applied in coumarins, giving the ability for the synthesis of linear *ortho*-diacylsubstituted derivatives. The presence of two acyl groups at neighboring positions is always desirable in aromatic derivatives. However, there are no other general methods for such derivatives.^[20] The transformation has been proven to be the most appropriate way to synthesize *ortho*-diacylsubstituted heterocycles. The simplicity of the method, the low cost of the reagents, and the good yield add to the synthetic value of the transformation. In addition, 6,7-diacyl-coumarins 4 could also serve as very useful intermediates to various heterocycles with possible pharmaceutical properties.

EXPERIMENTAL

All the solvents for the reactions and chromatography were purchased from Merck, whereas all hydrazides 2 from Aldrich. Compound 5 was

| | | • | • | | • | | | |
|-------------------|------------------------------------|---------------------------------|----------------|----------------------|------------|------------------------|------------------------|----------------------|
| | | | Reagent | | | | Yield (%) | |
| Compound | R | Reagents method A (Method B) | molar ratio | Reaction time (h) | Solvent | Reaction temp. (°C) | method A (Method B) | Mp (°C) ^a |
| 3a | Ph | 1 + 2a | 1/1 | 24 | PrOH | Reflux | 92 | 286-288 |
| 3b | 2'-HOC ₆ H ₄ | 1+2b | 1/1 | 24 | PrOH | Reflux | 80 | 328–330 |
| 3с | $2'-O_2NC_6H_4$ | 1+2c | 1/1 | 24 | PrOH | Reflux | 88 | 251–252 |
| 3d | 2'-furyl | 1+2d | 1/1 | 24 | PrOH | Reflux | 89 | 227-228.5 |
| 3e | 2'-thienyl | 1+2e | 1/1 | 24 | PrOH | Reflux | 83 | 284–286 |
| 3f | Me | 1 + 2f | 1/1 | 24 | PrOH | Reflux | 75 | 319–321 |
| $\mathbf{4a}^{b}$ | Ph | 3a + LTA | 1/1.5 | 2 | THF | rt rt | 68 | 166 - 167 |
| | | (3a + 7a + LTA) | | | | rt | (44) | |
| $\mathbf{4b}^{b}$ | $2'-HOC_6H_4$ | 3b + LTA | 1/1.5 | 24 | THF | rt | 67 | 186 - 188 |
| | | (3b + 7b + LTA) | | | | | (48) | |
| $4c^b$ | $2'-O_2NC_6H_4$ | 3c + LTA | 1/2 | 2 | THF | rt | 61 | 152 - 154 |
| | | (3c + 7c + LTA) | | | | | (36) | |
| $4\mathbf{d}^b$ | 2'-furyl | 3d + LTA | 1/2.3 | 24 | THF | rt | 09 | 194 - 196 |
| | | (3d + 7d + LTA) | | | | | (35) | |
| $4e^b$ | 2'-thienyl | 3e + LTA | 1/1.5 | 24 | THF | rt | 64 | 178.5 - 180 |
| | | (3e + 7e + LTA) | | | | | (38) | |
| | | 3e + PID | 1/2 | 24 | CH_2CI_2 | ц | 09 | |
| $\mathbf{4f}^{b}$ | Me | 3f + LTA | 1/2 | 24 | THF | 0 | 73 | 128 - 130 |
| | | (3f + 7f + LTA) | | | | | (48) | |

Table 1. Preparation of 6-acetyl-7-hydroxycoumarin *N*-acylhydrazones **3** and 6.7-diacylcoumarins **4**

4000

 ^{a}Mps are uncorrected. $^{b}Compounds$ **4a**-**4f** were recrystallized from ethanol.

Downloaded by [Dalhousie University] at 01:41 20 September 2012

prepared according to the literature procedure.^[18] Compound 1 was prepared according to the literature procedure^[18] with additional two columns of chromatography and a recrystallization of the final obtained fraction mixture of 1+6 (Scheme 2). Thin-layer chromatography (TLC) plates were Merck plastic plates with silica gel 60 F₂₅₄ (70–230 mesh). Column chromatography was performed on silica gel 60 F₂₅₄ (70–230 mesh). Column chromatography was performed on a Bruker Avance 400 spectrometer (¹H MHz 400.15, ¹³C 100.62 MHz) in dimethyl sulfoxide (DMSO) using the signal of the solvent as the internal standard (residual DMSO for ¹H: δ 2.50 ppm, ¹³C δ 39.5 ppm). Either elemental analysis or exact mass measurement have been provided for all the new compounds **3** and **4**.

Typical Procedure for Formation of 6-Acetyl-7-hydroxycoumarin *N*-Acylhydrazones 3

A mixture of 6-acetyl-7-hydroxycoumarin 1 (5 mmol) and the corresponding hydrazide in molar ratio 1:1 were refluxed in propanol-1 (20 ml) for 24 h. The mixture was allowed to cool, and the precipitate was filtered and subsequently dried to afford the pure products 3 as white solids (Table 1).

Typical Procedure for Formation of 6,7-Diacylcoumarins 4 (Method A)

Lead tetracetate was added to a stirred solution of hydrazone **3** (1 mmol) in tetrahydrofuran (THF) (20 ml), in an ice bath. The molar ratio of hydrazone/lead tetraacetate (LTA) and the reaction times are presented in Table 1. The mixture was then stirred at rt. The oily product obtained after filtration of lead diacetate and condensation of the filtrate was subjected to column chromatography (silica gel 70–230 mesh) and was eluted with a mixture of petroleum ether/ethylacetate 1:1 to afford the pure products **4** as white solids (Table 1).

Typical Procedure for Formation of 6,7-Diacylcoumarins 4 (Method B)

A mixture of 6- and 8-acetyl-7-hydroxycoumarin 1 and 6 (5 mmol), prepared according to the literature procedure, $^{[18]}$ was treated with the appropriate hydrazide 2, in molar ratio 1:1, under reflux in propanol-1 (20 ml), for 24 h. The mixture was allowed to cool, and the precipitate was filtered and subsequently dried to afford mixtures of hydrazones 3 and 7. These mixtures of hydrazones were further used without any purification. Thus, lead tetracetate was added to a stirred solution of the mixture of **3** and **7** (1 mmol) in THF (20 ml), in an ice bath. The molar ratio of the mixture of hydrazones/LTA and the reaction time are presented in Table 1. The reaction mixture was then stirred at rt. The oily product obtained after filtration of lead diacetate and condensation of the filtrate was subjected to column chromatography (silica gel 70–230 mesh) and was eluted with a mixture of petroleum ether/ ethylacetate 1:1 to afford the pure products **4** as white solids (Table 1).

Oxidation of Hydrazone 3e with PID

Phenyliodosodiacetate (PID) was added to a stirred solution of hydrazone **3e** (1 mmol) in dichloromethane (20 ml) in an ice bath. The molar ratio of hydrazone/LTA and the reaction time are presented in Table 1. The mixture was then stirred at rt. The oily product obtained after condensation of the solvent was subjected to column chromatography (silica gel 70–230 mesh) and was eluted with a mixture of petroleum ether/ethylacetate 1:1 to afford the pure coumarin **4e** as white solid (Table 1).

Data on Compound 3a

¹H NMR (400 MHz, DMSO-d₆): δ 2.51 (s, 3H), 6.27 (d, 1H, J = 9.3 Hz), 6.85 (s, 1H), 7.55–7.63 (m, 3H), 7.93–8.05 (m, 4H), 11.45 (s, 1H), 14.27 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 14.2, 103.8, 111.1, 112.3, 117.2, 128.1 128.4, 129.3, 132.1, 132.7, 144.4, 155.7, 156.9, 160.0, 162.4, 164.5; MS m/z (ES+): 345 (M+23), 323 (M+1); CHN: C, 67.01%; H, 4.43%; N, 8.70%. Calculated for C₁₈H₁₄N₂O₄: C, 67.07%; H, 4.38%; N, 8.69%.

Data on Compound 3b

¹H NMR (400 MHz, DMSO-d₆): δ 2.40 (s, 3H), 6.27 (d, 1H, J = 9.4 Hz), 6.86 (s, 1H), 6.96–7.02 (m, 2H), 7.41–7.45 (m, 1H), 7.93–7.98 (m, 2H), 8.03 (s, 1H), 11.40 (s, 1H), 11.69 (s, 1H), 12.18 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ too insoluble; HRMS (ESI+) m/z: calcd. for C₁₈H₁₄N₂O₅: 699.16976 (2M+Na); 361.07949 (M+Na); found: 699.16964 (2M+Na); 361.07891 (M+Na).

Data on Compound 3c

¹H NMR (400 MHz, DMSO-d₆): δ 2.47 (s, 3H), 6.27 (d, 1H, J = 9.4 Hz), 6.62 (s, 1H), 7.77–7.89 (m, 3H), 7.97 (d, 1H, J = 9.7 Hz), 8.04 (s, 1H), 8.19

(d, 1H, J=8.0 Hz), 11.4 (s, 1H), 11.8 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 14.2, 103.8, 111.2, 112.35, 117.1, 124.3, 129.5, 130.1, 130.5, 131.4, 134.2, 144.3, 146.6, 155.75, 156.3, 160.1, 162.2, 162.9; HRMS (ESI+) m/z calcd. for C₁₈H₁₃N₃O₆: 757.15009 (2M+Na), 390.06966 (M+Na); found: 757.15059 (2M+Na), 390.06929 (M+Na).

Data on Compound 3d

¹H NMR (400 MHz, DMSO-d₆): δ 2.47 (s, 3H), 6.27 (d, 1H, J = 9.5 Hz), 6.71 (d, 1H, J = 3.1 Hz), 6.84 (s, 1H), 7.41 (d, 1H, J = 3.3 Hz), 7.96–7.98 (m, 2H), 8.06 (s, 1H), 11.31 (s, 1H), 14.06 (s, 1H). Compound **3a** was too insoluble for ¹³C NMR; HRMS (ESI +) m/z calcd. for C₁₆H₁₂N₂O₅: 647.13847 (2M+23), 335.06380 (M+Na);found: 647.13924 (2M+Na), 335.06370 (M+Na).

Data on Compound 3e

¹H NMR (400 MHz, DMSO-d₆): δ 2.52 (s, 3H), 6.27 (d, 1H, J = 9.5 Hz), 7.24 (s, 1H), 7.91–7.92 (m, 2H), 7.95–7.98 (m, 2H), 8.05 (s, 1H), 11.37 (s, 1H), 14.07 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 14.4, 103.7, 111.1, 112.3, 117.2, 128.1, 129.4, 130.5, 132.6, 136.6, 144.35, 155.7, 156.8, 158.9, 160.0, 162.3; HRMS (ESI +) m/z calcd. for C₁₆H₁₂N₂O₄S: 679.09339 (2M+Na), 351.04155 (M+Na); found: 679.09440 (2M+Na), 351.04099 (M+Na).

Data on Compound 3f

Compound **3a** was too insoluble for H¹ and ¹³C NMR; HRMS (ESI+) m/z calcd. for C₁₃H₁₂N₂O₄: 543.14863 (2M+Na), 283.06893 (M+Na); found: 543.14873 (2M+2Na), 283.06915 (M+Na).

Data on Compound 4a

¹H NMR (400 MHz, DMSO-d₆): δ 2.53 (s, 3H), 6.64 (d, 1H, J = 9.7 Hz), 7.43–7.61 (m, 6H), 8.17 (d, 1H, J = 9.7 Hz), 8.55 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 27.6, 116.6, 118.5, 119.8, 129.3, 129.4, 129.5, 130.2, 132.1, 133.0, 133.8, 137.0, 144.1, 144.2, 156.5, 159.9, 195.8, 197.4; HRMS (ESI+) m/z calcd. for C₁₈H₁₂O₄: 293.08058 (M+H); found: 293.08084 (M+H).

Data on Compound 4b

¹H NMR (400 MHz, DMSO-d₆): δ 2.55 (s, 3H), 6.64 (d, 1H, J = 9.7 Hz), 6.80–6.81 (m, 1H), 6.96 (d, 1H, J = 8.2 Hz), 7.15 (d, 1H, J = 7.7 Hz), 7.44–7.49 (m, 2H), 8.16 (d, 1H, J = 9.7 Hz), 8.54 (s, 1H), 11.32 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 27.6, 116.4, 118.2, 118.5, 119.8, 119.9, 121.2, 132.1, 132.4, 132.7, 136.7, 143.1, 144.1, 156.4, 159.9, 161.2, 197.4, 200.6; MS m/z (ES+): 331 (M+23), 309 (M+1), 215; CHN: C, 69.84%; H, 3.72%. Calculated for C₁₈H₁₂O₅: C, 70.13%; H, 3.92%.

Data on Compound 4c

¹H NMR (400 MHz, DMSO-d₆): δ 2.53 (s, 3H), 6.69 (d, 1H, J=9.7 Hz), 7.45 (s, 1H), 7.56 (d, 1H, J=8.2 Hz), 7.78–7.85 (m, 2H), 7.11 (d, 1H, J=8.2 Hz), 8.16 (d, 1H, J=9.7 Hz), 8.27 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 28.4, 117.7, 119.0, 121.0, 124.5, 129.6, 130.6, 131.2, 133.2, 133.4, 135.7, 138.7, 143.0, 147.6, 154.6, 159.2, 192.25, 199.5; HRMS (ESI+) m/z calcd. for C₁₈H₁₁NO₆: 697.10650 (2M+Na), 360.04786 (M+2Na); found: 697.10710 (2M+Na), 360.04790 (M+Na).

Data on Compound 4d

¹H NMR (400 MHz, DMSO-d₆): δ 2.56 (s, 3H), 6.65–6.67 (m, 2H), 7.07 (d, 1H, J = 3,5 Hz), 7.53 (s, 1H), 7.96 (m, 1H), 8.16 (d, 1H, J = 9.7 Hz), 8.51 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 27.3, 113.1, 118.1, 119.4, 119.5, 122.0, 129.6, 131.0, 133.05, 141.8, 149.3, 151.6, 155.4, 159.25, 181.1, 197.3; HRMS (ESI+) m/z calcd. for C₁₆H₁₀O₅: 587.09487 (2M+23), 305.04204 (M+Na); found: 587.09477 (2M+Na), 305.04183 (M+Na).

Data on Compound 4e

¹H NMR(400 MHz, DMSO-*d*₆): δ 2.53 (s, 3H), 6.64 (d, 1H, *J*=9.7 Hz), 7.43–7.57 (m, 2H), 7.59–7.61 (m, 2H), 8.17 (d, 1H, *J*=9.7 Hz), 8.55 (s, 1H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ 27.6, 116.6, 118.5, 119.8, 129.3, 129.4, 132.1, 133.0, 133.85, 137.0, 144.1, 144.2, 156.5, 159.9, 195.8, 197.4; MS (ESI+) *m/z*: 321 (M+Na), 215; CHN: C, 64.06%; H, 3.30%. Calculated for C₁₆H₁₀O₄S: C, 64.42%; H, 3.38%.

Data on Compound 4f

¹H NMR (400 MHz, DMSO-d₆): δ 2.43 (s, 3H), 2.52 (s, 3H), 6.60 (d, 1H, J = 9.5 Hz), 7.54 (s, 1H), 8.07 (d, 1H, J = 9.5 Hz), 8.22 (s, 1H); ¹³C NMR (100 MHz, DMSO-d₆): δ 28.6, 30.2, 116.0, 116.7, 120.2, 130.6, 133.8, 143.7, 144.4, 155.8, 159.9, 199.4, 202.0; MS (ESI+) m/z: 253 (M+Na), 231 (M+H); CHN: C, 67.66%; H, 4.30%. Calculated. for C₁₃H₁₀O₄: C, 67.82%; H, 4.38%.

ACKNOWLEDGMENT

The authors are grateful to the Royal Society of Chemistry for financial support of this work.

REFERENCES

- Weinmamm, I. In *Coumarins: Biology, Applications and Modes of Actions*; R. O'Kennedy, R. D. Thornes (Eds.); John Wiley: London, England, 1997; pp. 1–22.
- (a) Riordan, D. J.; Daly, I. The growth-inhibiting properties of lactones. *Ir. J. Med. Sci.* 1954, *6*, 157–161; (b) Bose, P. K. On some biochemical properties of natural coumarins. *J. Indian Chem. Soc.* 1958, *58*, 367–375.
- Kostova, I. Synthetic and natural coumarins as cytotoxic agents. Curr. Med. Chem.-Anti Cancer Agents 2005, 5, 29–46.
- Tanaka, T.; Kumamoto, T.; Ishikawa, T. Enantioselective total synthesis of anti-HIV-1 active (+)-calanolide A through a quinine-catalyzed asymmetric intramolecular oxo-Michael addition. *Tetrahedron Lett.* 2000, *41*, 10229– 10232.
- Jung, J.-C.; Kim, J.-C.; Park, O. S. A convenient one-pot synthesis of 4-hydroxycoumarin, 4-hydroxythiocoumarin, and 4-hydroxyquinolin-2(1h)one. Synth. Commun. 2001, 31, 1195–1200.
- Jung, J.-C.; Kim, J.-C.; Park, O. S. Simple and cost effective syntheses of 4-hydroxycoumarin. Synth. Commun. 1999, 29, 3587–3595.
- Musicki, B.; Periers, A.-M.; Laurin, P.; Ferroud, D.; Benedetti, Y.; Lachaud, S.; Chatreaux, F.; Haesslein, J.-L.; Iltis, A.; Pierre, C.; Khider, J.; Tessot, N.; Airault, M.; Demassey, J.; Dupuis-Hamelin, C.; Lassaigne, P.; Bonnefoy, A.; Vicat, P.; Klich, M. Improved antibacterial activities of coumarin antibiotics bearing 5',5'-dialkylnoviose: Biological activity of RU79115. *Bioorg. Med. Chem. Lett.* 2000, *10*, 1695–1699.
- Soine, T. O. Naturally occurring coumarins and related physiological activities. J. Pharm. Sci. 1964, 53, 231–264.
- Casley-Smith, J. R.; Casley-Smith, J. R. In *Coumarins: Biology, Applications,* and Modes of Actions; R. O'Kennedy, R. D. Thornes (Eds.); John Wiley: England, 1997; pp. 143–184.

- Kostova, I. Synthetic and natural coumarins as antioxidants. *Mini-Reviews in Med. Chem.* 2006, 6, 365–374.
- Lee, S.; Sivakumar, K.; Shin, W.-S.; Xie, W.; Wang, Q. Synthesis and anti-angiogenesis activity of coumarins derivatives. *Bioorg. Med. Chem. Lett.* 2006, 16, 4596–4599.
- Ivie, G. W.; Holt, D. L.; Ivey, M. C. Natural toxicants in human foods: Psoralens in raw cooked parsnip root. *Science* 1981, 213, 909–910.
- Kleiner, H. E.; Vulimiri, S. V.; Miller, L.; Johnson, W. H: Whitman, C. P.; DiGiovanni, J. Oral administration of naturally occurring coumarins leads to altered phase I and II enzyme activities and reduced DNA adduct formation by polycyclic aromatic hydrocarbons in various tissues of SENCAR mice. *Carcinogenesis* 2001, 22, 73–82.
- Prince, M.; Campbell, C. T.; Robertson, T. A.; Wells, A. J.; Kleiner, H. E. Naturally occurring coumarins inhibit 7,12-dimethylbenz[α]anthracene DNA adduct formation in mouse mammary gland. *Carcinogenesis* 2006, 29, 1204–1213.
- Nam, N.-H.; Kim, Y.; You, Y.-J.; Hong, D.-H.; Ahn, B.-Z. Preliminary structure-antiangiogenic activity relationships of 4-senecioyloxymethyl-6,7dimethoxy-coumarin. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 2345–2348.
- Kotali, A.; Lafazanis, I. S.; Harris, P. A. A novel and facile synthesis of 7,8-diacylcoumarins. *Tetrahedron Lett.* 2007, 48, 7181–7183.
- Kotali, A. Reactions of hydrazones with lead tetraacetate. *Curr. Org. Chem.* 2002, 26, 965–985.
- Abramov, M. A.; Dehaen, W. A novel approach to sulphide derivatives of furocoumarin natural products. *Synthesis* 2000, 1529–1531.
- Katritzky, A. R.; Harris, P. A.; Kotali, A. Mechanism of the replacement of phenolic hydroxyl by carbonyl on lead tetraacetate treatment of o-hydroxylaryl ketone acylhydrazones. J. Org. Chem. 1991, 56, 5049–5051.
- 20. Kotali, A.; Harris, P. A. o-Diacylbenzenes in organic synthesis. A Review. *Org. Prep. Proc. Int.* **2003**, *35*, 583–601.